Theravance Biopharma, Inc.TBPH
What Theravance Biopharma, Inc. does.
Theravance Biopharma, Inc. (“we,” “our,” “Theravance Biopharma” or the “Company”) is a biopharmaceutical company primarily focused on the development and commercialization of medicines. Our focus is to deliver medicines that make a difference ® in people’s lives.
In pursuit of our purpose, we leverage decades of expertise, which has led to the development of the United States (“US”) Food and Drug Administration (the “FDA”) approved YUPELRI ® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (“COPD”).
On March 3, 2026, we announced that our ampreloxetine Phase 3 clinical study (CYPRESS) in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment composite score. As a result of this outcome, we have decided to wind down the ampreloxetine program.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $71.9M | $55.3M | $51.3M | $57.4M | $64.4M | $107.5M |
| Net income | -$278.0M | -$199.4M | $872.1M | -$55.2M | -$56.4M | $105.9M |
| Free cash flow | -$257.0M | -$211.3M | -$187.6M | -$29.5M | -$11.9M | $238.5M |
More on TBPH.
- Theravance Biopharma, Inc. summary
- Theravance Biopharma, Inc. financial statements
- Theravance Biopharma, Inc. key metrics
- Theravance Biopharma, Inc. health scores and style box
- Theravance Biopharma, Inc. earnings
- Theravance Biopharma, Inc. dividends
- Theravance Biopharma, Inc. valuation
- Theravance Biopharma, Inc. ownership and insiders
- Theravance Biopharma, Inc. peers
Figures from Theravance Biopharma, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.